Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
A vaccine protecting women against placental malaria could be based on the sub-domains of the VAR2CSA antigen, since antibodies against the DBL4ɛ-ID4 subunit of the VAR2CSA protein can inhibit parasite binding to the placental ligand chondroitin sulphate A (CSA). Here we tested the ability of DBL4ɛ-ID4 to induce binding-inhibitory antibodies when formulated with adjuvants approved for human use. We have characterized the immune response of DBL4ɛ-ID4 in combination with Freund's complete and incomplete adjuvant and with three adjuvants currently being used in clinical trials: Montanide(®) ISA 720, Alhydrogel(®) and CAF01. Antibodies induced against DBL4ɛ-ID4 in combination with these adjuvants inhibited parasite binding to CSA from 82% to 99%. Although, different epitope recognition patterns were obtained for the different formulations, all adjuvant combinations induced strong Th1 and Th2 type responses, resulting in IgG with similar binding strength, with to the DBL4ɛ-ID4 antigen. These results demonstrate that the DBL4ɛ-ID4 antigen is highly immunogenic and that binding inhibitory antibodies are induced when formulated with any of the tested adjuvants.
OriginalsprogEngelsk
TidsskriftVaccine
Vol/bind30
Udgave nummer3
Sider (fra-til)572-9
Antal sider8
ISSN0264-410X
DOI
StatusUdgivet - 2012

ID: 36494338